QuidelOrtho Corporation

Equities

QDEL

US2197981051

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX 19:01:10 19/07/2024 BST 5-day change 1st Jan Change
34.08 USD +2.64% Intraday chart for QuidelOrtho Corporation +5.25% -53.76%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
RBC Cuts Price Target on QuidelOrtho to $61 From $68, Keeps Outperform Rating MT
QuidelOrtho Seeks Inorganic Options CI
Transcript : QuidelOrtho Corporation Presents at The 44th Annual William Blair Growth Stock Conference, Jun-05-2024 01:20 PM
QuidelOrtho Opens New Distribution Center in Pedricktown, NJ CI
Activist Jana Partners built position in QuidelOrtho in first quarter, sources say RE
Sector Update: Health Care Stocks Rise in Late Afternoon Trading MT
Jana Partners Acquires Stake in QuidelOrtho MT
Activist Jana Partners built position in QuidelOrtho in first quarter, sources say RE
RBC Cuts Price Target on QuidelOrtho to $68 From $81, Keeps Outperform Rating MT
Tranche Update on QuidelOrtho Corporation's Equity Buyback Plan announced on August 17, 2022. CI
Transcript : QuidelOrtho Corporation, Q1 2024 Earnings Call, May 08, 2024
Earnings Flash (QDEL) QUIDELORTHO CORPORATION Posts Q1 Revenue $711M, vs. Street Est of $695.1M MT
Earnings Flash (QDEL) QUIDELORTHO CORPORATION Reports Q1 EPS $0.44, vs. Street Est of $0.40 MT
QuidelOrtho Corporation Suspends Earnings Guidance for the Year 2024 CI
QuidelOrtho Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
QuidelOrtho Corporation Announces CEO Changes CI
QuidelOrtho Corporation Appoints Brian J. Blaser as President and to the Board CI
QuidelOrtho Shares Fall on Decision to Withdraw FDA 510(k) Submission for Savanna RVP4+ Assay MT
QuidelOrtho Gets US FDA Clearance For QuickVue COVID-19 Test MT
QuidelOrtho Corporation Receives FDA 510(K) Clearance for its QuickVue COVID-19 Test CI
QuidelOrtho Receives Canada's Approval for Triage PLGF Test to Detect Pregnancy Complications MT
Transcript : QuidelOrtho Corporation Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-05-2024 04:00 PM
Sector Update: Health Care Stocks Mixed Late Afternoon MT
Sector Update: Health Care MT
QuidelOrtho Shares Decline Following UBS Downgrade MT
Chart QuidelOrtho Corporation
More charts
QuidelOrtho Corporation is engaged in vitro diagnostics, developing and manufacturing intelligent solutions. The Company sells its products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other point-of-care (POC) settings, blood banks and donor centers, as well as for individual, non-professional, over the counter (OTC) use. The Company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Connect, Ortho Plus, Ortho Vision, QuickVue, Quidel, QuidelOrtho, QVue, Savanna, Sofia, Solana, Thyretain, Triage, Virena, Vitros among others. It provides support for its customers across more than 130 countries and territories.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
33.2 USD
Average target price
50 USD
Spread / Average Target
+50.60%
Consensus
  1. Stock Market
  2. Equities
  3. QDEL Stock
  4. News QuidelOrtho Corporation
  5. UBS Downgrades QuidelOrtho to Sell From Neutral, Adjusts Price Target to $42 From $70